Supplementary to: GCC GLP-1 Market Sentiment Report (9 March 2026)
Date 29 March 2026
Period reviewed 10–23 March 2026, with reference back to the Ramadan-period baseline
Markets UAE (primary signal), Saudi Arabia, Bahrain, Kuwait, Qatar, Oman
Purpose Quick pulse assessment to evaluate whether GCC sentiment has evolved and whether a 'new normal' is emerging

1. Summary

The GCC GLP-1 category was heading toward a more stable, clinically guided state as Ramadan progressed. The Ramadan-era shift toward medical supervision, safe continuation, and away from casual use appeared to be consolidating. However, the Iran conflict (from 28 February) has fundamentally disrupted the post-Ramadan transition. Eid al-Fitr fell on 19–20 March, and we are only 2–3 days past it. The expected post-Ramadan rebound in new-start demand and consumer-led energy has not yet materialised visibly — partly because it is too early, and partly because the regional crisis has overtaken the normal seasonal rhythm.

There are early signs of a more mature category, but it is too early to confirm a settled 'new normal'. The direction of travel is toward stabilisation, but it is being stress-tested by forces outside the category itself.

2. What changed since the previous pulse

Development What happened Why it matters for Lilly
Iran conflict escalated US-Israeli strikes on Iran (28 Feb) triggered Iranian retaliation against GCC states. Major airports (Dubai, Abu Dhabi, Doha) closed or severely restricted. Strait of Hormuz effectively blocked. No longer a 'watchout' — it is a live operational disruption affecting pharmaceutical supply chains across the GCC.
Cold-chain supply confirmed vulnerable Logistics firms (Kuehne+Nagel, Marken, DHL) confirm active rerouting of temperature-sensitive pharma cargo through Jeddah, Riyadh, Oman, Istanbul. No confirmed widespread GLP-1 stock-outs yet, but executives warn Gulf inventories could run down within weeks if conflict persists. GLP-1 injectables are refrigerated products in the highest-risk category for disruption. Treatment-continuity messaging is now operationally urgent, not just good positioning.
UAE regulator asserts stockpile security Emirates Drug Establishment issued public statement via WAM confirming UAE strategic stockpile is secure and sufficient for local demand. Stabilising institutional signal, but not GLP-1-specific and does not address cold-chain logistics for individual product categories.
Semaglutide patent expired in India (20 March) 40+ Indian manufacturers launched generic semaglutide within 48 hours. Prices crashed from ~$94–175/month to as low as ~$14/month. Affects semaglutide (Ozempic/Wegovy) — not tirzepatide (Mounjaro). GCC patent status not publicly confirmed. Generics can't legally be exported to patent-protected markets. But the pricing narrative is now global and will reach GCC consumers.
Cleveland Clinic weight-regain study (12 March) ~8,000 patients studied. Obesity group regained average of just 0.5% body weight after one year (vs. 50%+ in earlier clinical trials). Key finding: most patients restart, switch, or adopt structured lifestyle support. Directly counters the 'lifetime dependency' and 'dramatic rebound' narratives gaining traction in GCC media. Covers both semaglutide and tirzepatide.
Post-Eid demand signals not yet readable No fresh post-Eid clinic campaigns, restart promotions, or media features have surfaced in the 2–3 days since Eid. News cycle dominated by conflict. The expected post-Ramadan demand bounce may still come, but cannot be confirmed from observable evidence yet.
Clinical tone from Ramadan is holding Provider messaging in the UAE (Burjeel, Fakeeh, DarDoc, GluCare, Metabolic Health) remains doctor-led and safety-focused. No visible reversion to consumer hype. Mounjaro continues to be described as the most-requested product by UAE pharmacy managers.
Novo Nordisk maintaining active UAE advertising Google Ads Transparency data shows Novo Nordisk A/S running approximately 20 ads in the UAE over the last 30 days via novocare.global. Creative is disease-awareness and consultation-led: BMI calculators, 'Champion a lighter you today,' 'Feel lighter. Live better.' Not product-specific. Novo is building awareness and consultation intent while Lilly has no equivalent visible presence. Consistent with Lilly's cautious posture but worth tracking as a competitive gap.
Meta ad activity is provider-led Meta Ad Library shows significant GLP-1 advertising volume in the UAE from clinics, hospitals, obesity specialists, and treatment programmes — not from manufacturers. Confirms original report's finding: the market is being won through the care pathway, not just the molecule.
UAE search data shows Zepbound entering awareness Google Trends shows "zepbound" as a BREAKOUT rising query in the UAE for the first time. Mounjaro searches up +40%. Ozempic declining to third position behind Wegovy and Mounjaro. Directly relevant to Lilly. Consumers are discovering the weight-loss tirzepatide brand even before formal UAE availability. Mounjaro's momentum is confirmed and strengthening.
Oral format demand is measurable and bilingual "Wegovy pills" up +20%. "Weight loss pills" is BREAKOUT. "Wegovy حبوب" (Arabic: "wegovy pills") is also BREAKOUT. Oral GLP-1 demand has penetrated both English and Arabic-speaking audiences. Strongest forward-looking signal for Lilly's orforglipron. There is already a measurable consumer base actively searching for pill-format GLP-1 in both languages. When orforglipron reaches the UAE, it will capture existing demand, not need to create it.

3. Are we seeing a new normal?

Assessment

Sentiment has evolved, but it is too early to call a new normal.

Evidence for stabilisation